Arcturus Therapeutics Holdings (ARCT) Cash from Operations (2018 - 2026)

Arcturus Therapeutics Holdings has reported Cash from Operations for 9 years, with the latest figure at 19441000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 44.67% year-over-year to 19441000.0; the trailing twelve-month figure through Mar 2026 stood at 58574000.0 (up 34.43% YoY), and the FY2025 full-year result was 74271000.0, down 24.31% from the prior year.
• Cash from Operations for Q1 2026 stood at 19441000.0, down from 16227000.0 in the prior quarter.
• The five-year high for Cash from Operations was 160259000.0 in Q4 2022, with the low at 49039000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 8209705.88 across 5 years, with a median of 19441000.0 in 2026.
• Annual changes were most pronounced in 2022 — Cash from Operations soared 477.11% — and 2025, when it sank 5613.73%.
• Arcturus Therapeutics Holdings' Cash from Operations stood at 160259000.0 in 2022, then sank by 100.39% to 629000.0 in 2023, then soared by 54.85% to 284000.0 in 2024, then slumped by 5613.73% to 16227000.0 in 2025, then slipped by 19.81% to 19441000.0 in 2026.
• The last three Cash from Operations figures came in at 19441000.0 (Q1 2026), 16227000.0 (Q4 2025), and 17151000.0 (Q3 2025), per Business Quant data.